Enteropathogenic Escherichia coli use redundant tyrosine kinases to form actin pedestals

被引:92
作者
Swimm, A
Bommarius, B
Li, Y
Cheng, D
Reeves, P
Sherman, M
Veach, D
Bornmann, W
Kalman, D [1 ]
机构
[1] Emory Univ, Dept Pathol & Lab Med, Grad Program, Atlanta, GA 30322 USA
[2] Emory Univ, Dept Microbiol & Mol Genet, Grad Program, Atlanta, GA 30322 USA
[3] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
关键词
D O I
10.1091/mbc.E04-02-0093
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Enteropathogenic Escherichia coli (EPEC) are deadly contaminants in water and food and induce protrusion of actin-rich membrane pedestals beneath themselves upon attachment to intestinal epithelia. EPEC then causes intestinal inflammation, diarrhea, and, among children, death. Here, we show that EPEC uses multiple tyrosine kinases for formation of pedestals, each of which is sufficient but not necessary. In particular, we show that Abl and Arg, members of the Abl family of tyrosine kinases, localize and are activated in pedestals. We also show that pyrido[2,3-d]pyrimidine (PD) compounds, which inhibit Abl, Arg, and related kinases, block pedestal formation. Finally, we show that Abl and Arg are sufficient for pedestal formation in the absence of other tyrosine kinase activity, but they are not necessary. Our results suggest that additional kinases that are sensitive to inhibition by PD also can suffice. Together, these results suggest that EPEC has evolved a mechanism to use any of several functionally redundant tyrosine kinases during pathogenesis, perhaps facilitating its capacity to infect different cell types. Moreover, PD compounds are being developed to treat cancers caused by dysregulated Abl. Our results raise the possibility that PD may be useful in treating EPEC infections, and because PD affects host and not bacterium, selecting resistant strains may be far less likely than with conventional antibiotics.
引用
收藏
页码:3520 / 3529
页数:10
相关论文
共 61 条
[51]  
Smith JM, 2002, FRONT BIOSCI, V7, pD31
[52]   COMBINED DEFICIENCIES OF SRC, FYN, AND YES TYROSINE KINASES IN MUTANT MICE [J].
STEIN, PL ;
VOGEL, H ;
SORIANO, P .
GENES & DEVELOPMENT, 1994, 8 (17) :1999-2007
[53]  
Swedlow J., 1997, DECONVOLUTION IMAGES, V2, P284
[54]  
TANAKA M, 1995, MOL CELL BIOL, V15, P6829
[55]   The Src-selective kinase inhibitor PP1 also inhibits Kit and Bcr-Abl tyrosine kinases [J].
Tatton, L ;
Morley, GM ;
Chopra, R ;
Khwaja, A .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (07) :4847-4853
[56]   Genetically encoded fluorescent reporters of protein tyrosine kinase activities in living cells [J].
Ting, AY ;
Kain, KH ;
Klemke, RL ;
Tsien, RY .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (26) :15003-15008
[57]   NEONATAL LETHALITY AND LYMPHOPENIA IN MICE WITH A HOMOZYGOUS DISRUPTION OF THE C-ABL PROTOONCOGENE [J].
TYBULEWICZ, VLJ ;
CRAWFORD, CE ;
JACKSON, PK ;
BRONSON, RT ;
MULLIGAN, RC .
CELL, 1991, 65 (07) :1153-1163
[58]  
WANG JYJ, 1988, ONCOGENE RES, V3, P293
[59]  
Wisniewski D, 2002, CANCER RES, V62, P4244
[60]   Modulation of the F-actin cytoskeleton by c-Abl tyrosine kinase in cell spreading and neurite extension [J].
Woodring, PJ ;
Litwack, ED ;
O'Leary, DDM ;
Lucero, GR ;
Wang, JYJ ;
Hunter, T .
JOURNAL OF CELL BIOLOGY, 2002, 156 (05) :879-892